GLP-1 Agonists
GLP-1 Agonists are a class of medications that mimic the action of the hormone glucagon-like peptide-1, primarily used for the treatment of type 2 diabetes and obesity. They function by enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety.
Mechanism of Action
- Insulin Secretion: Stimulates pancreatic beta cells to release insulin in response to elevated blood glucose levels.
- Glucagon Suppression: Inhibits alpha cells from releasing glucagon, reducing hepatic glucose production.
- Gastric Emptying: Delays gastric emptying, leading to prolonged nutrient absorption and increased feelings of fullness.
- Central Appetite Regulation: Acts on receptors in the hypothalamus to reduce food intake and caloric consumption.
Clinical Applications
- Type 2 Diabetes: First-line or adjunctive therapy for glycemic control.
- Chronic Weight Management: Approved for obesity treatment (BMI ≥30, or ≥27 with comorbidities) due significant weight loss outcomes.
Notable Agents
- Semaglutide: Ozempic (diabetes), Wegovy (obesity).
- Tirzepatide: Mounjaro (diabetes), Zepbound (obesity). Note: Technically a dual GIP/GLP-1 receptor agonist.
- Liraglutide: Victoza, Saxenda.
- Dulaglutide: Trulicity.
Challenges & Considerations
- Supply Constraints: High global demand has led to periodic shortages.
- Side Effects: Nausea, vomiting, diarrhea, and potential risks of pancreatitis or gallbladder disease.
- Long-term Efficacy: Concerns regarding weight regain upon cessation of therapy.
- Muscle Mass Loss: Rapid weight loss may include lean muscle mass reduction; resistance training is often recommended.
Integrated Analysis: Kurzgesagt (2026-05-20)
See detailed breakdown in Ozempic & GLP-1 Agonists: Revolutionizing Obesity Treatment and Challenges.
Key Insights
- Medical Revolution: Positioned as a transformative shift in obesity management, moving beyond behavioral interventions to physiological modulation.
- Dual Impact: Addresses both metabolic health (diabetes) and anthropometric metrics (weight), suggesting potential for broader metabolic disease prevention.
- Uncomfortable Truths:
- Highlights the gap between clinical success and societal stigma surrounding obesity treatment.
- Discusses the economic implications of widespread adoption and healthcare system burden.
- Notes the psychological dependency on pharmacological aid versus lifestyle change adherence.
See Also
- Metabolic Syndrome
- Type 2 Diabetes Mellitus
- Obesity
- Hormonal Regulation of Appetite